Inicio
Autor Carlos Esteban Builes Montaño
|
Comentario :
Médico Internista Endocrinólogo, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (41)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaCombining GLP?1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique / Carlos Esteban Builes Montaño ; Yepes Cortés, Carlos A. ; Cardenas Moreno, Isabel C. ; Daza Arnedo, Rodrigo ; Feriz Bonelo, Karen M. ; Yama Mosquera, Erica ; Ramirez Rincón, Alex H. ; Castillo Barrios, Gilberto A. ; Suarez Rodriguez, Andres F. ; Carreño Jiménez, Johanna
Título : Combining GLP?1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Yepes Cortés, Carlos A., Autor ; Cardenas Moreno, Isabel C., Autor ; Daza Arnedo, Rodrigo, Autor ; Feriz Bonelo, Karen M., Autor ; Yama Mosquera, Erica, Autor ; Ramirez Rincón, Alex H., Autor ; Castillo Barrios, Gilberto A., Autor ; Suarez Rodriguez, Andres F., Autor ; Carreño Jiménez, Johanna, Autor Fecha de publicación : 2025 Títulos uniformes : Diabetes Therapy Idioma : Inglés (eng) Palabras clave : Diabetes mellitus; Diabetes complications; Glucagon-like peptide 1 receptor agonists; Sodium-glucose cotransporter 2 inhibitors Resumen : Introduction Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, diabetes management has relied on stepwise medication addition based on failures in glucose control. However, the benefits and risks of combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain inadequately understood. Methods This study conducted a scoping review to examine the available clinical research on the benefits and risks of combining GLP1-RAs and SGLT2is. Additionally, the nominal group technique was used to gather insights from medical experts from different areas regarding the combined therapy’s daily clinical use, concerns, and limitations. The review followed the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Result The final report includes 50 studies. The most common designs are observational studies. The median (IQR) number of patients across studies was 355 (1295). Studies reporting metabolic outcomes were the most common. The follow-up time ranges from 1.5 to 60 months. Although limited, the available evidence seems to support the combined use of GLP1-RAs and SGLT2is. The experts agreed that the underlying mechanisms appear synergistic rather than antagonistic for most outcomes. Conclusions Combining medical therapy is common in diabetes treatment and may occur naturally in everyday practice. Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes. Quality evidence and better-defined outcomes are paramount to guide the selection of patients for combined therapy. Mención de responsabilidad : Carlos A. Yepes?Cortés · Isabel C. Cardenas?Moreno · Rodrigo Daza?Arnedo · Karen M. Feriz?Bonelo · Erica Yama?Mosquera · Alex H. Ramirez?Rincón · Gilberto A. Castillo?Barrios · Andres F. Suarez?Rodriguez · Johanna Carreño?Jiménez · Carlos E. Builes?Montaño Referencia : Diabetes Ther (2025) 16:813–849 DOI (Digital Object Identifier) : 10.1007/s13300-025-01722-x. Derechos de uso : CC BY-NC-ND En línea : https://link.springer.com/article/10.1007/s13300-025-01722-x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Combining GLP?1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Yepes Cortés, Carlos A., Autor ; Cardenas Moreno, Isabel C., Autor ; Daza Arnedo, Rodrigo, Autor ; Feriz Bonelo, Karen M., Autor ; Yama Mosquera, Erica, Autor ; Ramirez Rincón, Alex H., Autor ; Castillo Barrios, Gilberto A., Autor ; Suarez Rodriguez, Andres F., Autor ; Carreño Jiménez, Johanna, Autor . - 2025.
Obra : Diabetes Therapy
Idioma : Inglés (eng)
Palabras clave : Diabetes mellitus; Diabetes complications; Glucagon-like peptide 1 receptor agonists; Sodium-glucose cotransporter 2 inhibitors Resumen : Introduction Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, diabetes management has relied on stepwise medication addition based on failures in glucose control. However, the benefits and risks of combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain inadequately understood. Methods This study conducted a scoping review to examine the available clinical research on the benefits and risks of combining GLP1-RAs and SGLT2is. Additionally, the nominal group technique was used to gather insights from medical experts from different areas regarding the combined therapy’s daily clinical use, concerns, and limitations. The review followed the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Result The final report includes 50 studies. The most common designs are observational studies. The median (IQR) number of patients across studies was 355 (1295). Studies reporting metabolic outcomes were the most common. The follow-up time ranges from 1.5 to 60 months. Although limited, the available evidence seems to support the combined use of GLP1-RAs and SGLT2is. The experts agreed that the underlying mechanisms appear synergistic rather than antagonistic for most outcomes. Conclusions Combining medical therapy is common in diabetes treatment and may occur naturally in everyday practice. Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes. Quality evidence and better-defined outcomes are paramount to guide the selection of patients for combined therapy. Mención de responsabilidad : Carlos A. Yepes?Cortés · Isabel C. Cardenas?Moreno · Rodrigo Daza?Arnedo · Karen M. Feriz?Bonelo · Erica Yama?Mosquera · Alex H. Ramirez?Rincón · Gilberto A. Castillo?Barrios · Andres F. Suarez?Rodriguez · Johanna Carreño?Jiménez · Carlos E. Builes?Montaño Referencia : Diabetes Ther (2025) 16:813–849 DOI (Digital Object Identifier) : 10.1007/s13300-025-01722-x. Derechos de uso : CC BY-NC-ND En línea : https://link.springer.com/article/10.1007/s13300-025-01722-x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002356 AC-2025-039 Archivo digital Producción Científica Artículos científicos Disponible
Título : Combining Glucagon-Like Peptide-1 Receptor agonists and Sodium-Glucose Cotransporter-2 Inhibitors in the management of Type 2 Diabetes Mellitus: A protocol for a scoping review Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Suarez Rodriguez, Andres F., Autor ; Carreño, Johanna, Autor Fecha de publicación : 2025 Títulos uniformes : F1000Research Idioma : Inglés (eng) Palabras clave : Diabetes mellitus; Glucagon-like peptide-1 receptor agonists; Sodium-glucose cotransporter-2 inhibitors. Resumen : Introduction Diabetes treatment has evolved from solely focusing on glucose control to a more patient-centered approach that includes medications designed to reduce specific risks in addition to managing blood glucose control. Methods and analysis We propose a scoping review to explore the available clinical research on the combined use of GLP-1RAs and SGLT2is. This review will adhere to the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). Mención de responsabilidad : Carlos E. Builes-Montaño https://orcid.org/0000-0002-2418-61592,3, Andres F. Suarez-Rodriguez1, Johanna Carreño1 DOI (Digital Object Identifier) : 10.12688/f1000research.159628.1 Derechos de uso : CC BY-NC-ND En línea : https://f1000research.com/articles/14-202 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Combining Glucagon-Like Peptide-1 Receptor agonists and Sodium-Glucose Cotransporter-2 Inhibitors in the management of Type 2 Diabetes Mellitus: A protocol for a scoping review [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Suarez Rodriguez, Andres F., Autor ; Carreño, Johanna, Autor . - 2025.
Obra : F1000Research
Idioma : Inglés (eng)
Palabras clave : Diabetes mellitus; Glucagon-like peptide-1 receptor agonists; Sodium-glucose cotransporter-2 inhibitors. Resumen : Introduction Diabetes treatment has evolved from solely focusing on glucose control to a more patient-centered approach that includes medications designed to reduce specific risks in addition to managing blood glucose control. Methods and analysis We propose a scoping review to explore the available clinical research on the combined use of GLP-1RAs and SGLT2is. This review will adhere to the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). Mención de responsabilidad : Carlos E. Builes-Montaño https://orcid.org/0000-0002-2418-61592,3, Andres F. Suarez-Rodriguez1, Johanna Carreño1 DOI (Digital Object Identifier) : 10.12688/f1000research.159628.1 Derechos de uso : CC BY-NC-ND En línea : https://f1000research.com/articles/14-202 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002341 AC-2025-024 Archivo digital Producción Científica Artículos científicos Disponible
Título : Direct costs of severe hypoglycemia events in individuals with diabetes mellitus: a perspective from the Colombian health system - a single-center study Tipo de documento : documento electrónico Autores : Michael Andrés García Rivera, Autor ; Natalia Andrea Rojas Henao, Autor ; Hernández Herrera, Ana C., Autor ; Juliana Díaz Giraldo, Autor ; Carlos Esteban Builes Montaño, Autor Fecha de publicación : 2025 Títulos uniformes : Hospital Practice Idioma : Inglés (eng) Palabras clave : Diabetes mellitus; Latin America; cost of illness; diabetes complications; hypoglycemia Resumen : Background and aims: Diabetes mellitus is one of the more prevalent chronic diseases globally, and healthcare expenditures for diabetes care are on the rise. Intensive diabetes treatment has been associated with reducing the risk of chronic complications. However, hypoglycemia, the most common adverse effect, poses a significant risk to individuals' lives and is linked to high costs for healthcare systems. Methods: We conducted a retrospective cross-sectional study to determine direct costs by identifying emergency room visits due to hypoglycemia events using diagnostic codes during January 2017 to June 2019. Direct costs were calculated using billed data from the payer and information on outpatient treatment regimens. Differences in median costs were estimated based on length of stay and type of outpatient treatment. Results: Data from 101 patients and the same number of events were included. Women represented (62.4%) of the patients, the median age was 70 (IQR 59.5-80). Blood glucose levels at admission ranged from 12 mg/dL to 67 mg/dL. Most patients were on insulin for outpatient treatment. The median cost of care per hypoglycemia episode was US $345.35 (IQR US $202-727.8), and the cost per episode was higher in patients treated with regimens that included sulfonylureas. Conclusions: The management of patients admitted to the emergency department with a diagnosis of hypoglycemia places a significant burden on the Colombian healthcare system, primarily due to the associated hospitalization costs. Patients treated with regimens that included sulfonylureas incurred higher costs per episode. Prevention, patient education, and individualized treatment approaches could help alleviate the burden of hypoglycemia on both patients and the healthcare system. Mención de responsabilidad : Rojas-Henao, Natalia A; Garcia-Rivera, Michael; Hernandez-Herrera, Ana C.; Díaz-Giraldo, Juliana; Builes-Montaño, Carlos E. Referencia : Hosp Pract (1995). 2025 Feb;53(1):2439775 DOI (Digital Object Identifier) : 10.1080/21548331.2024.2439775 PMID : 39648816 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39648816/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Direct costs of severe hypoglycemia events in individuals with diabetes mellitus: a perspective from the Colombian health system - a single-center study [documento electrónico] / Michael Andrés García Rivera, Autor ; Natalia Andrea Rojas Henao, Autor ; Hernández Herrera, Ana C., Autor ; Juliana Díaz Giraldo, Autor ; Carlos Esteban Builes Montaño, Autor . - 2025.
Obra : Hospital Practice
Idioma : Inglés (eng)
Palabras clave : Diabetes mellitus; Latin America; cost of illness; diabetes complications; hypoglycemia Resumen : Background and aims: Diabetes mellitus is one of the more prevalent chronic diseases globally, and healthcare expenditures for diabetes care are on the rise. Intensive diabetes treatment has been associated with reducing the risk of chronic complications. However, hypoglycemia, the most common adverse effect, poses a significant risk to individuals' lives and is linked to high costs for healthcare systems. Methods: We conducted a retrospective cross-sectional study to determine direct costs by identifying emergency room visits due to hypoglycemia events using diagnostic codes during January 2017 to June 2019. Direct costs were calculated using billed data from the payer and information on outpatient treatment regimens. Differences in median costs were estimated based on length of stay and type of outpatient treatment. Results: Data from 101 patients and the same number of events were included. Women represented (62.4%) of the patients, the median age was 70 (IQR 59.5-80). Blood glucose levels at admission ranged from 12 mg/dL to 67 mg/dL. Most patients were on insulin for outpatient treatment. The median cost of care per hypoglycemia episode was US $345.35 (IQR US $202-727.8), and the cost per episode was higher in patients treated with regimens that included sulfonylureas. Conclusions: The management of patients admitted to the emergency department with a diagnosis of hypoglycemia places a significant burden on the Colombian healthcare system, primarily due to the associated hospitalization costs. Patients treated with regimens that included sulfonylureas incurred higher costs per episode. Prevention, patient education, and individualized treatment approaches could help alleviate the burden of hypoglycemia on both patients and the healthcare system. Mención de responsabilidad : Rojas-Henao, Natalia A; Garcia-Rivera, Michael; Hernandez-Herrera, Ana C.; Díaz-Giraldo, Juliana; Builes-Montaño, Carlos E. Referencia : Hosp Pract (1995). 2025 Feb;53(1):2439775 DOI (Digital Object Identifier) : 10.1080/21548331.2024.2439775 PMID : 39648816 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39648816/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002357 AC-2025-040 Archivo digital Producción Científica Artículos científicos Disponible
Título : A scoping review of the extent of the clinical research on the vitiligo extent score Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Orozco Jiménez, Sara, Autor ; Rueda Galvis, Paola, Autor ; Arango Salgado, Andrea, Autor Fecha de publicación : 2025 Títulos uniformes : Archives of Dermatological Research Idioma : Inglés (eng) Palabras clave : Feasibility; Outcome measurement; Reliability; Vitiligo; Vitiligo extent score Resumen : Vitiligo is a chronic skin condition with no cure. Clinical assessment and treatment evaluation rely heavily on clinometry tools and expert knowledge. The Vitiligo Extent Score has been proposed as one of the most reliable and easy-to-use clinometry tools for vitiligo. We conducted a scoping review to identify all evidence on clinical research for the Vitiligo Extent Score. Databases searched included: MEDLINE (PubMed), Embase, Open Grey, Lens, and Directory of Open Access Journals (DOAJ). We followed the approach proposed in the Joanna Briggs Institute Reviewer’s Manual and reported this review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. The results are presented in sections covering VES reliability, its smallest detectable change, minimally important change, modifications proposed to the instrument, an extension of cross-cultural validation, and comparison to other clinical scoring instruments. The systematic review identified 42 records, and 23 studies were included in the final report. The VES demonstrated good or excellent reliability across different clinical scenarios and when used by experts and non-experts. The VES has a low minimally important change that overlaps with the smallest detectable change. The instrument has been modified for various clinical scenarios, including perifollicular assessment, patient-oriented scoring, and target evaluation. To date, the VES has only been cross-culturally validated outside its developmental population for patients in Thailand. Finally, the VES has been used in clinical research to assess disease severity, its correlation with other variables, evaluate vitiligo response to therapy, and develop disease extent scores. The VES is highly reliable, easy to use, and versatile for clinical research and everyday clinical assessment. However, more cross-cultural validations are needed to extend its applicability. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025. Mención de responsabilidad : Gustavo Adolfo Triana?Rodriguez5 | Mónica Royero?Arias6 | Jessica Echeverry, Tamara Gamo, Luz ÁngelaMoreno, Olga Lucía Baquero, Luz Marina Mejía, Sonia Restrepo?Gualteros, Luis Miguel Navarro?Ramirez, Sergio Moreno?Lopez, Juan Gabriel Piñeros, Carlos Álvarez?Moreno, Alejandro Díaz?Díaz, Iván Felipe Gutierrez, Clara Galvis Diaz, José Manuel Nieto, Irati Gastesi, Cinta Moraleda, Alfredo Tagarro García, Andrea Ramirez Varela. Referencia : Arch Dermatol Res . 2025 Feb 26;317(1):498. doi: 10.1007/s00403-024-03778-4. DOI (Digital Object Identifier) : 10.1007/s00403-024-03778-4 PMID : 40009214 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40009214/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis A scoping review of the extent of the clinical research on the vitiligo extent score [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Orozco Jiménez, Sara, Autor ; Rueda Galvis, Paola, Autor ; Arango Salgado, Andrea, Autor . - 2025.
Obra : Archives of Dermatological Research
Idioma : Inglés (eng)
Palabras clave : Feasibility; Outcome measurement; Reliability; Vitiligo; Vitiligo extent score Resumen : Vitiligo is a chronic skin condition with no cure. Clinical assessment and treatment evaluation rely heavily on clinometry tools and expert knowledge. The Vitiligo Extent Score has been proposed as one of the most reliable and easy-to-use clinometry tools for vitiligo. We conducted a scoping review to identify all evidence on clinical research for the Vitiligo Extent Score. Databases searched included: MEDLINE (PubMed), Embase, Open Grey, Lens, and Directory of Open Access Journals (DOAJ). We followed the approach proposed in the Joanna Briggs Institute Reviewer’s Manual and reported this review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. The results are presented in sections covering VES reliability, its smallest detectable change, minimally important change, modifications proposed to the instrument, an extension of cross-cultural validation, and comparison to other clinical scoring instruments. The systematic review identified 42 records, and 23 studies were included in the final report. The VES demonstrated good or excellent reliability across different clinical scenarios and when used by experts and non-experts. The VES has a low minimally important change that overlaps with the smallest detectable change. The instrument has been modified for various clinical scenarios, including perifollicular assessment, patient-oriented scoring, and target evaluation. To date, the VES has only been cross-culturally validated outside its developmental population for patients in Thailand. Finally, the VES has been used in clinical research to assess disease severity, its correlation with other variables, evaluate vitiligo response to therapy, and develop disease extent scores. The VES is highly reliable, easy to use, and versatile for clinical research and everyday clinical assessment. However, more cross-cultural validations are needed to extend its applicability. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025. Mención de responsabilidad : Gustavo Adolfo Triana?Rodriguez5 | Mónica Royero?Arias6 | Jessica Echeverry, Tamara Gamo, Luz ÁngelaMoreno, Olga Lucía Baquero, Luz Marina Mejía, Sonia Restrepo?Gualteros, Luis Miguel Navarro?Ramirez, Sergio Moreno?Lopez, Juan Gabriel Piñeros, Carlos Álvarez?Moreno, Alejandro Díaz?Díaz, Iván Felipe Gutierrez, Clara Galvis Diaz, José Manuel Nieto, Irati Gastesi, Cinta Moraleda, Alfredo Tagarro García, Andrea Ramirez Varela. Referencia : Arch Dermatol Res . 2025 Feb 26;317(1):498. doi: 10.1007/s00403-024-03778-4. DOI (Digital Object Identifier) : 10.1007/s00403-024-03778-4 PMID : 40009214 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40009214/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002348 AC-2025-031 Archivo digital Producción Científica Artículos científicos Disponible
Título : Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Londoño Bustamante, Andrés Felipe, Autor ; Julio Andrés Valencia Ferro, Autor ; Duque, Carlos S., Autor ; Tobón Ospina, Catalina, Autor ; Alejandro Vélez Hoyos, Autor ; Sánchez, Juan G., Autor ; Agudelo, Miguel, Autor ; Dueñas, Juan P., Autor ; Palacio, Maria F., Autor ; Sierra, Natalia, Autor Fecha de publicación : 2025 Títulos uniformes : Cureus Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave : classification prognosis risk staging surgery thyroid cancer tnm Resumen : The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as “microcarcinomas.” Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today’s decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety. Mención de responsabilidad : Carlos S. Duque , Carlos E. Builes-Montaño , Catalina Tobón-Ospina , Alejandro Velez Hoyos , Juan G. Sánchez , Andres F. Londoño , Miguel Agudelo , Julio A. Valencia , Juan P. Dueñas , Maria F. Palacio , Natalia Sierra Referencia : Cureus 17(4): e81972. DOI (Digital Object Identifier) : 10.7759/cureus.81972 Derechos de uso : CC BY-NC-ND En línea : https://www.cureus.com/articles/350600-thyroid-cancer-staging-historical-evoluti [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Londoño Bustamante, Andrés Felipe, Autor ; Julio Andrés Valencia Ferro, Autor ; Duque, Carlos S., Autor ; Tobón Ospina, Catalina, Autor ; Alejandro Vélez Hoyos, Autor ; Sánchez, Juan G., Autor ; Agudelo, Miguel, Autor ; Dueñas, Juan P., Autor ; Palacio, Maria F., Autor ; Sierra, Natalia, Autor . - 2025.
Obra : Cureus
Idioma : Inglés (eng) Idioma original : Inglés (eng)
Palabras clave : classification prognosis risk staging surgery thyroid cancer tnm Resumen : The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as “microcarcinomas.” Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today’s decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety. Mención de responsabilidad : Carlos S. Duque , Carlos E. Builes-Montaño , Catalina Tobón-Ospina , Alejandro Velez Hoyos , Juan G. Sánchez , Andres F. Londoño , Miguel Agudelo , Julio A. Valencia , Juan P. Dueñas , Maria F. Palacio , Natalia Sierra Referencia : Cureus 17(4): e81972. DOI (Digital Object Identifier) : 10.7759/cureus.81972 Derechos de uso : CC BY-NC-ND En línea : https://www.cureus.com/articles/350600-thyroid-cancer-staging-historical-evoluti [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002371 AC-2025-054 Archivo digital Producción Científica Artículos científicos Disponible
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
